Categories: News

Delivra Health Brands Announces Grant of Incentive Stock Options

Vancouver, British Columbia–(Newsfile Corp. – May 28, 2024) – Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) (“Delivra Health” or the “Company“), a consumer packaged goods company uniquely positioned in the health and wellness sector, is pleased to announce that pursuant to a resolution passed by the Company’s Board of Directors on May 28, 2024, it has granted an aggregate of 14,000,000 incentive stock options (the “Options“) under the Company’s 10% fixed stock option plan, to certain directors, officers and employees of the Company. The Options are exercisable at a price of $0.05 per common share, will have a term of five years from the date of grant, and will vest 1/3 annually from the date of grant. The Options are subject to the terms and conditions prescribed by the TSX Venture Exchange, and applicable securities laws.

About Delivra Health Brands Inc.

Helping people take control of their health with alternative wellness solutions is what energizes the Delivra Health team! The Delivra Health portfolio features innovative brands like Dream Water® and LivRelief™, which deliver relief from common everyday issues like chronic pain, anxiety, and sleeplessness. Delivra Health products have allowed millions of customers to reclaim their mobility, energy, and in turn, quality of life. The websites of the Company’s two subsidiaries are  Dream Water® and  LivReliefTM. For more information, please visit  www.delivrahealthbrands.com.

Investor Relations:
Jack Tasse
Chief Financial Officer
IR@delivrahealth.com
1-877-915-7934

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/210861

Staff

Recent Posts

2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement

Black Book Research Q4 flash survey shows health plans shifting from effort-based sourcing to KPI-backed…

9 hours ago

Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy

CHICAGO, IL / ACCESS Newswire / December 24, 2025 / Healthcare investors have seen this…

12 hours ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon…

12 hours ago

PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

12 hours ago

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec.…

12 hours ago